Drug Trial Radar · NCT01714713
A 26-Week Extension Study of EVP-6124 (Alpha-7 nAChR) as an Adjunctive Pro-Cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic Therapy
Last checked: Nov 20, 2026Latest source record: May 3, 2016 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
830
Actual
Start
Jun 2013
Primary completion
Oct 2015
Study completion Oct 2015
Sponsor
- Lead sponsor
- FORUM Pharmaceuticals IncIndustry
- Sponsor type
- Industry
- Collaborators
- Syneos Health
- First posted
- Oct 26, 2012
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 50 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is being conducted to further investigate the safety of prolonged exposure to EVP-6124 in subjects with Schizophrenia receiving a stable dose of an atypical antipsychotic who completed double-blind treatment on studies EVP-6124-015 and EVP-6124-016.
Conditions
- Schizophrenia
- Impaired Cognition
Interventions
EVP-6124Drug
Arm 1, 2
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety and Tolerability of EVP-6124 or Placebo in Subjects with SchizophreniaTime frame: Baseline through Day 182 or Early Termination
Locations
128 sites in 16 countries. Site status is shown where the registry gives one.
Site not named
Little Rock, Arkansas
Site not named
Anaheim, California
Site not named
Bellflower, California
Site not named
Cerritos, California
Site not named
Chino, California
Site not named
Costa Mesa, California
Site not named
Culver City, California
Site not named
Downey, California
Site not named
Escondido, California
Site not named
Garden Grove, California
Site not named
Glendale, California
Site not named
Los Angeles, California
Site not named
Mesa, California
Site not named
Norwalk, California
Site not named
Oakland, California
Site not named
Oceanside, California
Site not named
Orange, California
Site not named
Riverside, California
Site not named
San Diego, California
Site not named
San Gabriel, California
Site not named
Santa Ana, California
Site not named
Sherman Oaks, California
Site not named
Torrance, California
Site not named
Washington D.C., District of Columbia
Site not named
Lauderhill, Florida
Site not named
Miami, Florida
Site not named
Miami Springs, Florida
Site not named
North Miami, Florida
Site not named
Oakland Park, Florida
Site not named
Orange City, Florida
Site not named
Orlando, Florida
Site not named
Atlanta, Georgia
Site not named
Marietta, Georgia
Site not named
Smyrna, Georgia
Site not named
Chicago, Illinois
Site not named
Oak Brook, Illinois
Site not named
Oak Park, Illinois
Site not named
Wichita, Kansas
Site not named
Lake Charles, Louisiana
Site not named
Shreveport, Louisiana
Showing 40 of 128 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.